SL Swiss Lipid Navigator
Demonstration prototype — synthetic data only, simplified rules, not for clinical use.
Step 10 of 10 · Decision support

Summary

What this step shows

All results for this patient in one view, with the reasoning behind each step. Update any value and the results are recalculated.

Daniel Huber
DEMO-5 · 62 years · Male · born 26.05.1964 · LDL-C measured 19.08.2026
Update lab values
Clinical pathwayPrimary Prevention — Diabetes pathway
Risk categoryHigh
LDL-C (current)2.1 mmol/L
LDL-C target<1.8 mmol/L
Current treatmentHigh-intensity statin (Atorvastatin 80 mg) + ezetimibe
Recommended next stepConsider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)
Swiss reimbursement Not eligible
Missing criteria
  • Specialist confirmation not documented.
Reasoning by step
  1. Step 5 — Clinical pathway View details →
    Primary Prevention — Diabetes pathway

    No established CVD, but diabetes is present, so a diabetes-adjusted risk methodology applies.

  2. Step 6 — Cardiovascular risk View details →
    High

    Simplified demo scoring (age + smoking + blood pressure + baseline LDL-C) → 5 points → High risk. This is illustrative only, not the licensed ESC calculator.

  3. Step 7 — LDL-C target View details →
    <1.8 mmol/L

    High risk → target <1.8 mmol/L.

  4. Step 8 — Treatment plan View details →
    Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)

    Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.

  5. Step 9 — Swiss reimbursement View details →
    Not eligible

    One or more demo reimbursement criteria are not yet met — see missing criteria below.

Demonstration output based on simplified rules — not clinical advice. Generated 02.11.2026 19:08.

← Swiss reimbursement
Back to patients →